Stratipath Breast Achieves CE Marking Under IVDR, Reinforcing Its leading position in AI-Based Breast Cancer Precision Diagnostics
16 June 2026
Stratipath, today announced that Stratipath Breast has received CE marking
Being a leader in the field of AI-based precision diagnostics, Stratipath is constantly moving forward and evolving to provide new tools and strategies for improving patient outcomes. Keep track of developments in our news feeds, or follow us on LinkedIn or Twitter.
Being a leader in the field of AI-based precision diagnostics, Stratipath is constantly moving forward and evolving to provide new tools and strategies for improving patient outcomes. Keep track of developments in our news feeds, or follow us on LinkedIn or Twitter.
Stratipath, today announced that Stratipath Breast has received CE marking
new validation data for prognostic performance of Stratipath Breast in
Helsinki University Hospital (HUS), Finland’s largest healthcare provider and one
Stratipath Breast will be available within PathAI’s AISight® Dx Image
Stratipath and Visiopharm, today announced a strategic collaboration to combine
First world health tech: Press Release Stratipath releases biopsy capability
Stratipath, today announced that Stratipath Breast has received CE marking
new validation data for prognostic performance of Stratipath Breast in
Helsinki University Hospital (HUS), Finland’s largest healthcare provider and one
First world health tech: Press Release Stratipath releases biopsy capability
The ESMO Daily Reporter recently published a summary of the
A method for spatial interpretation of weakly supervised deep learning